Is adjuvant therapy a potential road for fighting Mycobacterium tuberculosis resistance?

References

• WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO, Geneva, Switzerland (2011).
   Google Scholar
• Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66(7), 1417–1430 (2011).
   PubMed Web of Science ®Google Scholar
• da Silva PE, Von Groll A, Martin A, Palomino JC. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 63(1), 1–9 (2011).
   PubMed Web of Science ®Google Scholar
• Machado D, Couto I, Perdigão J et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 7(4), e34538 (2012).
   PubMed Web of Science ®Google Scholar
• Viveiros M, Leandro C, Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. Int. J. Antimicrob. Agents 22(3), 274–278 (2003).
   PubMed Web of Science ®Google Scholar
• Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201(8), 1225–1231 (2010).
   PubMed Web of Science ®Google Scholar
• Jabes D. The antibiotic R&D pipeline: an update. Curr. Opin. Microbiol. 14(5), 564–569 (2011).
   PubMed Web of Science ®Google Scholar
• Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat. Rev. Drug Discov. 11(3), 171–172 (2012).
   PubMed Web of Science ®Google Scholar
• Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13(11), 908–914 (1994).
   PubMed Web of Science ®Google Scholar
• Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59(6), 1237–1246 (2007).
   PubMed Web of Science ®Google Scholar
• Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob. Agents Chemother. 56(5), 2643–2651 (2012).
   PubMed Web of Science ®Google Scholar
• Martins M, Viveiros M, Couto I, Amaral L. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. Int. J. Tuberc. Lung Dis. 13(5), 569–573 (2009).
   PubMed Web of Science ®Google Scholar
• Amaral L, Viveiros M, Kristiansen JE. ‘Non-antibiotics’: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr. Drug Targets 7(7), 887–891 (2006).
   PubMed Web of Science ®Google Scholar
• Martins M, Dastidar SG, Fanning S et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int. J. Antimicrob. Agents 31(3), 198–208 (2008).
   PubMed Web of Science ®Google Scholar
• van Ingen J. The broad-spectrum antimycobacterial activities of phenothiazines, in vitro: somewhere in all of this there may be patentable potentials. Recent Pat. Antiinfect. Drug Discov. 6(2), 104–109 (2011).
   PubMedGoogle Scholar
• Martins M, Schelz Z, Martins A et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 29(3), 338–340 (2007).
   PubMed Web of Science ®Google Scholar
• Abbate E, Vescovo M, Natiello M et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J. Antimicrob. Chemother. 67(2), 473–477 (2012).
   PubMed Web of Science ®Google Scholar
• Martins M. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB) – a novel, patentable approach to limit the emergence of XDR-TB. Recent Pat. Antiinfect. Drug Discov. 6(2), 110–117 (2011).
   PubMedGoogle Scholar
• Adams KN, Takaki K, Connolly LE et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145(1), 39–53 (2011).
   PubMed Web of Science ®Google Scholar
• Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int. J. Antimicrob. Agents 39(5), 376–380 (2012).
   PubMed Web of Science ®Google Scholar